



Universiteit
Leiden
The Netherlands

The role of the ubiquitin system in human cytomegalovirus-mediated degradation of MHC class I heavy chains

Hassink, G.C.

Citation

Hassink, G. C. (2006, May 22). *The role of the ubiquitin system in human cytomegalovirus-mediated degradation of MHC class I heavy chains*. Retrieved from <https://hdl.handle.net/1887/4414>

Version: Corrected Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/4414>

Note: To cite this publication please use the final published version (if applicable).

CHAPTER 9 SUMMARY & DISCUSSION

Parts of this chapter have been published in Current Topics in Microbiology and Immunology 300 (1995) pp57-94

One of the mechanisms used by HCMV to downregulate cell surface expression of the MHC class I complex involves the dislocation of newly synthesized class I heavy chains into the cytosol, where they are degraded by the proteasome^{1,2}. Misfolded ER proteins have been found to be degraded via the same route that HCMV uses to dispose of MHC class I molecules (reviewed in^{3,4}). The ubiquitin system plays an important role in this process⁵⁻¹⁰. In this thesis, the role of ubiquitin in the US2- and US11-dependent dislocation of MHC class I heavy chains has been studied. In this chapter, the results of this exploration are summarized and discussed.

MHC class I is only one of many immune evasion targets in CMV infection

Different species of CMV have developed different strategies to elude the immune system. This is exemplified by the diversity of immune evasion strategies identified for human and murine CMV^{11,12}, and recently, also for rat CMV¹³ (**Chapter 2**). All these CMV species downmodulate MHC class I expression at the cell surface. As mentioned in the introduction (**Chapter 1**), HCMV downregulates MHC class I cell surface expression through multiple mechanisms, including retention in the ER¹⁴⁻¹⁷, dislocation to the cytosol^{1,2,18,19} and hindrance of class I maturation by the inhibition of peptide translocation by TAP²⁰⁻²³. MCMV, on the other hand, downregulates class I at the cell surface by preventing the export of class I complexes from the post-ER/early Golgi^{24,25} and by lysosomal degradation²⁶. RCMV adopts yet another strategy in that it only delays MHC class I maturation without any obvious degradation, resulting in a temporary downregulation at the cell surface (**Chapter 2**).

The downregulation of MHC class I molecules at the cell surface of RCMV-infected cells is observed during the first 24 hours of infection (**Chapter 2**). Immune escape during the early stage of infection could be important for the survival and replication of cytomegaloviruses in mammalian cells²⁷⁻²⁹. In cells infected with cytomegaloviruses, it has been shown that the first immune evasion genes are expressed as early as 4 hours after infection^{30,31}. At later time points, MHC class I presentation is restored by the action of INF γ and TNF^{32,33}. Direct targeting of MHC class I molecules may, therefore, be the preferred first line of defense of the herpes virus at this early time point but it is not ideal in the long run, since downregulation of MHC class I at the cell surface is an unobvious way of immune evasion and may attract the attention of NK cells³⁴⁻³⁶.

The role of E3 ligases in the dislocation and degradation of ER (glyco)proteins

In the introduction it has been described how ubiquitin plays a role in

the degradation of ER proteins, in particular, US2- and US11-mediated degradation of class I heavy chains (**Chapter 1**). Not only the proteasomal degradation of class I molecules, but also their retrograde transport to the cytosol is dependent on ubiquitination. This is illustrated by experiments in which ubiquitination is blocked by a temperature-sensitive mutation in the ubiquitin activating enzyme (E1). At the restrictive temperature, the class I heavy chains are retained in the ER membrane. Other substrates, including mutated ribophorin I and TCR α chains, are retained in the ER when ubiquitination is inhibited^{5,37}. Shamu and colleagues have shown that ubiquitinated MHC class I species could be found attached to the ER of cells transfected with US11⁸. By expressing US11 and class I in these cells we were able to prove that US11-mediated dislocation also depended on a functional ubiquitin system (**Chapter 3**)⁷.

Several E3s were screened for their potential involvement in US11-dependent degradation. A RING mutant of the mammalian HRD1 (**Chapter 4**) did not influence US11-mediated degradation, despite the fact that we were able to show inhibition of degradation of two other ER degradation substrates, TCR- α CD3- δ , with this RING mutant (**Chapter 4**)³⁸. Besides HRD1, we also screened TEB4, the mammalian homologue of doa10p, for involvement in US11-dependent degradation (**Chapter 5**). In a search for the genes responsible for the degradation of the cytosolic yeast mating factor- α 2, Doa10 was identified as a novel *S. cerevisiae* E3 ubiquitin ligase³⁹. Doa10 is a multi membrane-spanning RING finger-containing ubiquitin ligase that resides in the ER and the nuclear envelope³⁹. It promotes the ubiquitination of proteins with a degradation signal denoted Deg1, which is also present within the N-terminal 62 residues of yeast mating factor- α 2. Doa10 acts in conjunction with the E2 enzymes Ubc6 and Ubc7³⁹.

Doa10 harbors an unusual RING-finger configuration³⁹. Proteins containing this RING-CH motif have earlier been associated with transcriptional regulation and DNA binding⁴⁰⁻⁴³, and designated as PHD- or LAP- domain containing proteins^{44 41}. These proteins do not function as E3 ubiquitin ligases. Aravind and colleagues⁴⁵, however, were able to discern structural differences, apart from cysteine and histidine composition, making it possible to discriminate between RING-HC-containing proteins that act as ubiquitin ligases and PHD/LAP domain-containing proteins with other functions. This refinement places Doa10 in the family of E3 ligases and not in the PHD/LAP domain-containing group of proteins.

Since Doa10 is localized in the ER membrane, it was sensible to test whether Doa10 is involved in the degradation of ER proteins. Indeed, the degradation of the short-lived ER-resident E2 enzyme Ubc6 was markedly inhibited in a Doa10delta yeast mutant³⁹. Degradation of Pma1-D378N and

Ste6-166, both misfolded forms of yeast plasma-membrane proteins, takes place from the ER and also depends on Doa10p^{46,47}. It was found that the degradation of either of these proteins is independent of Hrd1p. The degradation of CPY*, which has been shown to depend on Hrd1p, was not influenced by Doa10⁴⁶⁻⁴⁸. These results suggest that Hrd1p and Doa10 cooperate in yeast ER protein degradation, each serving a distinct subset of ER-substrates. However, when human CFTR was ectopically expressed in yeast, its degradation depended on both Hrd1p and Doa10. This was illustrated by the strong effect of deleting both E3s, whereas deleting either of them separately yielded only modest effects on the degradation of CFTR⁴⁹. These data implicate that Hrd1p and Doa10 are capable of complementing each other in the degradation of a single substrate. When Hrd1p and Doa10 are both deleted, yeast cells become extremely sensitive to ER stress, as well as to cadmium treatment. Deletion of just one of the two genes only has modest effects³⁹. Hrd1p and Doa10p are also linked to the Cdc48p-Npl4p-Ufd1p complex. A temperature-sensitive mutation in Npl4p causes the malfunctioning of the Cdc48p-Npl4p-Ufd1p complex. The resulting accumulation of ubiquitinated proteins in the (ER-) membrane can be suppressed by deleting both Doa10 and Hrd1p⁵⁰. Together, these findings illustrate that both proteins have a complementary role in the degradation of ER proteins and the neutralization of ER stress in yeast.

We identified TEB4 as the mammalian homologue of yeast Doa10p (**Chapter 5**)⁵¹. It had originally been characterized as a transcript of the Cri-du-chat critical region on chromosome 5. It appears to be well-conserved, as genes with a high degree of homology to TEB4 occur in many species. TEB4 contains 13 predicted transmembrane regions and has a RING-CH domain near its N-terminus. It exhibits UBC7-dependent E3 ligase activity *in vitro*, which is also ubiquitin lysine 48-specific (**Chapter 5**)⁵¹. While it promotes its own degradation in a RING-finger and proteasome-dependent fashion (**Chapter 5**)⁵¹, other substrates for TEB4 have not been found as yet. We tested the effect of over-expression of TEB4 and its RING-finger mutant on US11-dependent dislocation of MHC class I molecules, and on the degradation of UBC6. No effect on the degradation of either of these substrates (Hassink et al. unpublished) was observed. The putative role for TEB4 in ER protein degradation is, however, supported by its homology with *S. cerevisiae* Doa10p³⁹, its ER localization, the large number of transmembrane regions, the involvement of lysine 48 of ubiquitin in its E3 ligase activity, the *in vitro* dependence on UBC7, and its RING domain-dependent degradation by the proteasome (**Chapter 5**)⁵¹.

Membrane-associated RING-CH (MARCH) proteins⁵², such as murine gammaherpesvirus 68 mK3 and Kaposi sarcoma herpesvirus encoded

kK3 and kK5, inhibit the expression of MHC class I complexes and the co-stimulatory molecules ICAM-1 and B7.2 on the cell surface⁵²⁻⁵⁹. These E3 ligases mediate ubiquitin-dependent internalization of receptor molecules and their degradation in an endolysosomal compartment. Neither TEB4 nor its RING-finger mutant affected the surface expression of such immunomodulatory molecules as MHC class I, Fas, Tfr, CD4, and B7.2 (Hassink et al. unpublished), suggesting that TEB4 does not share this function with some of the other MARCH proteins.

The role of ubiquitin in protein dislocation

The observation that the process of retrograde transport of ER proteins to the cytosol is dependent on ubiquitination⁸(**Chapter 3**)^{5,7}, not only raises questions concerning the E3 responsible for this process but also with regard to the specific role of ubiquitin-conjugation in this process. It is reasonable to assume that the degradation substrates become poly-ubiquitinated themselves⁶. However, ubiquitination of substrates before their dislocation is difficult to envisage for ER-luminal substrates or proteins that lack lysines in their cytosolic domains. Yet ubiquitination is essential for the retrotranslocation of ER-luminal substrates like CPY*⁶⁰ and mutated ribophorin I⁵. Two observations may provide hints for the explanation of this apparent paradox. First, it has been suggested that the dislocation may be divided into two distinct steps⁶¹. Substrates that were initially luminal could thus be ubiquitinated while associated to the cytosolic side of the ER membrane. This then may be essential for their actual release into the cytosol, which is thought to be directed by the p97-Ufd1-Npl4 complex^{61,62,131}.

The second observation that may explain the role of ubiquitin in dislocation of ER proteins involves TCR α and MHC class I heavy chains, well-known ER degradation substrates, each containing a number of lysines. However, removal of the lysines from the cytosolic tail of MHC class I heavy chains does not influence their dislocation or degradation⁶. Moreover, removal of all the lysines from the TCR α chain results in dislocation and proteasomal degradation with kinetics indistinguishable from that of wild-type TCR α ⁶³. These data indicate that although these proteins possess lysines accessible to the ubiquitination machinery, these are not important for the removal of the proteins to the cytosol. Ubiquitination may still take place at the N-terminus of the lysine-less TCR α chains to facilitate their release from the ER membrane. This would require their relocation to the cytosolic side of the ER membrane prior to ubiquitination. Yet, we have recently provided evidence that the N-terminus is also dispensable for ubiquitin-dependent dislocation. An MHC class I heavy chain with all its lysines mutated to arginines and its N-terminus blocked by the fusion of lysine-less ubiquitin

molecule to this N-terminus^{64,65}, was dislocated to the cytosol as the wild-type molecule in the presence of HCMV US11 (**Chapter 6**). As a result of the lack of ubiquitination sites, however, proteasomal degradation of the mutant heavy chains was much slower, resulting in the appearance of a deglycosylated intermediate in the absence of proteasomal inhibition (**Chapter 6**). In US2-expressing cells, these lysine-less heavy chains were not dislocated but remained stable in the membrane despite the fact that they could be found associated with US2 molecules (**Chapter 6**). In this respect, US2-mediated dislocation resembles HIV Vpu-induced dislocation of CD4⁶⁶. These experiments established that the ubiquitin machinery uses different target NH₂ groups to discriminate between the dislocation of ER substrates and the degradation of dislocated substrates by proteasomes, thus illustrating that dislocation and degradation are separate events. Furthermore, these data indicate that fundamental differences may exist between US2- and US11-mediated dislocation. But most importantly, the experiments suggest that dislocation of ER proteins to the cytosol does not necessarily involve ubiquitination of the substrate itself. Instead, ubiquitination of an adaptor molecule *in trans* may be an essential step in the dislocation reaction. This compels us to form a new hypothesis about the process of dislocation.

Differences between US2 and US11 dependent dislocation

Several publications suggest that US2 and US11 differ in their mechanisms to dislocate heavy chains to the cytosol. To begin with, US2 works at much lower concentrations than US11⁶⁷. This would suggest that US2 merely induces dislocation for newly synthesized class I molecules in general, were it not for the fact that US2 has rather specific substrate-binding requirements, which argues in favor of active participation of US2 in the dislocation of specific MHC class I haplotypes⁶⁸.

Unlike US2-mediated dislocation, US11-mediated dislocation of class I heavy chains depends on the small multi-spanning ER membrane protein Derlin-1, which can be found in complex with US11 but not US2^{69,70}. Remarkably, the degradation of US2 itself does depend on Derlin-1⁷⁰, which indicates that heavy chain dislocation and US2 dislocation are separate events and renders an earlier hypothesis that US2 functions by dislocating in complex with the heavy chain highly unlikely.

US2 and US11 also differ in their recognition patterns. US2 has a broader specificity in that it also targets MHC class II molecules for degradation⁷¹⁻⁷⁴. It would be interesting to ascertain whether US2 uses the same binding surface for the recognition for both class I and II⁶⁸.

Finally, US2 and US11 differ in the requirements concerning cytosolic domains. The cytosolic tail of the heavy chain may be used as a recognition

beacon for cytosolic factors like the proteasome or the p97-Ufd1-Npl4 complex. Whereas the cytosolic tail of the heavy chain is required for US11-dependent dislocation^{75,76}, depending on the experimental circumstances, the heavy chain tail can be omitted in US2-mediated dislocation^{68,76}. Looking at the cytosolic domains of US2 and US11 themselves, on the other hand, the situation is reversed. The tail of US2 is required for heavy chain dislocation, but the tail of US11 is not^{73,77}. It could be the case, therefore, that in US11-dependent dislocation the tail of the heavy chain is used to interact with proteasomes or p97 complexes, whereas in US2-mediated dislocation this function is performed by US2 itself.

Communication between the lumen of the ER and the cytosol

It is clear that US2 and US11-dependent dislocation depend on a functional ubiquitin system, the proteasome and the p97 complex (**Chapter 3, 5**)^{62,78}. How these three cytosolic components work together with the luminal side of the ER is not clear. The dependence on functional proteasomes, for instance, varies with the circumstances on the luminal side of the membrane, which is exemplified by experiments in β_2m -negative cells. β_2m binding is one of the prerequisites for MHC class I molecules to egress to the Golgi and beyond⁷⁹⁻⁸¹. The folding of heavy chains occurs in β_2m negative cells, but, in contrast to maturation in β_2m positive cells, a significant portion of the newly synthesized heavy chains in β_2m negative cells is found in a reduced state (**Chapter 7**)⁸². In U373 astrocytoma cells in which β_2m expression was knocked down by RNAi, it has been shown that US2 requires β_2m for the dislocation of heavy chains when the proteasome is inhibited⁷⁸. In β_2m negative FO-1 melanoma cells without proteasome inhibitor, however, both US2 and US11 are able to target heavy chains for dislocation, suggesting that, in principle, lack of β_2m is not sufficient to inhibit US2- and US11-mediated dislocation (**Chapter 7**). Yet again, a difference was found between US2 and US11 when the proteasome was inhibited. US11-dependent dislocation of human heavy chains and normal ER-associated degradation of human heavy chains due to lack of β_2m were much more sensitive to proteasomal inhibition than US2-dependent dislocation (**Chapter 7**)⁸². The different outcomes of the two experiments suggest that β_2m positively influences the degradation of heavy chains by US11. In either case, the proteasome has a strong influence on the efficiency of US2- and US11-mediated dislocation, as has been observed for many other cases of ER-associated degradation. These data indicate that the dislocation of ER proteins is not driven by a single component, but that the efficiency of the dislocation process is influenced by several components.

Dislocation in progress

The fact that the luminal portion of the heavy chain does not need to be ubiquitinated in order to be dislocated by US11 also raises the question whether heavy chains are extracted via their N-termini or their C-termini (**Chapter 6**). Several studies hypothesized that US11-dependent dislocation occurs from the N-terminus to the C-terminus, but this was based on the finding that ubiquitination of the heavy chain is required for its dislocation and that lysines in the cytosolic tail of the heavy chain are not required, suggesting that ER luminal-positioned lysines are used^{3,8,69}. Extraction via the N-terminus, however, is more complicated than C-terminal extraction as it involves a second contact with the membrane. Furthermore, the molecule has to bend and probably even unfold to make this possible. By determining the relative amounts of differently situated epitopes within dislocating heavy chains that were exposed to the cytosol during pulse labeling in the presence of US11, we observed that TM-proximal regions appeared in the cytosol prior to the N-terminus (**Chapter 8**). This suggests that, in the case of US11-mediated dislocation of heavy chains, extraction starts at the C-terminal end of the class I molecule.

In β_2m -negative cells, in which heavy chains are prone to ER-associated degradation, a relatively high number of heavy chains were observed to be in a reduced state (**Chapter 7**). Conversion of heavy chains to a reduced state may be a prerequisite for efficient dislocation. Co-precipitation of Sec61 β with dislocated MHC class I heavy chains in the presence of US2, as well as studies with Sec61 α mutants, suggest that the Sec61 complex acts as a dislocation channel^{1,83-85}. In this model, TRAM could facilitate the re-entry of multi-spanning membrane proteins into the translocon. The translocon has a diameter of only 40-60 Å⁸⁶, implying that substrates using this channel will probably have to be unfolded by ER resident-chaperones prior to dislocation. However, a number of studies suggest that this is not the case. MHC class I molecules with an N-terminally fused GFP can be detected fluorescently active in cytosol in the presence of US2, suggesting that the fusion protein was dislocated in a folded state⁸⁷. Another study shows that fusion of a dihydrofolate reductase (DHFR) domain to the N-terminus of MHC class I does not inhibit dislocation in the presence of metotrexate⁸⁸, which induces rigid folding in the DHFR domain. Both these studies point to dislocation in a folded state and require a more flexible diameter of the pore, as has already been suggested by others⁸⁹⁻⁹². We attempted to establish whether the ER-dislocation mechanism was also able to facilitate the dislocation of larger substrates by generating large degradation-prone complexes in the lumen of the ER, consisting of an antibody that recognized a tag within an MHC class I heavy chain (**Chapter 8**). The expression of HA tag-containing MHC class I




Figure 1. formation of the US11 dislocation complex. See text for explanation.

heavy chains in anti-HA antibody-producing hybridoma's resulted in the formation of class I-antibody complexes. We have been unable to obtain stable transfectants of these constructs in these hybridoma's, which may be related to toxicity of the class I heavy chain-antibody complexes for the cell (**Chapter 8**). Our transient experiments revealed, that the IgG heavy chains were more unstable in cells expressing HA-containing MHC class I heavy chains than in wild-type class I heavy chain transfectants (**Chapter 8**). This suggests that the IgG-MHC heavy chain interaction induced dislocation of

both molecules simultaneously and might imply that the IgG- and MHC-heavy chains are dislocated.

A model for US11-dependent dislocation

As mentioned earlier, the observation that US11-mediated dislocation is not dependent on ubiquitination of the MHC class I molecules combined with the observation that the dislocation process itself is dependent on ubiquitination, suggests that ubiquitination of an adaptor molecule *in trans* may be required. MHC class I-US11 complexes do not only co-precipitated with Derlin-1 and p97^{69,70}, but also with HRD1 and HERP⁹³⁻⁹⁵ (van Voorden unpublished).

Based on these results, the following model for US11-dependent dislocation can be envisaged (Figure 1). The first step is the recognition of MHC class I heavy chains by US11, which is in complex with Derlin-1 and the small membrane spanning molecule VIMP^{69,70}. The US11-Derlin-1-VIMP complex attracts the HERP-HRD1 complex (**Chapter 6**) which may be initiated by the ubiquitination of HERP or VIMP or other still unidentified components of the dislocation machinery⁶⁹. It is not certain whether the ubiquitination event required for dislocation is driven by HRD1, since a RING mutant of HRD1 is not able to inhibit US11-dependent dislocation³⁸. It is, however, possible that the transmembrane regions of Derlin-1 and the multi-membrane spanning HRD1 form a conduit around the heavy chain as was hypothesized for the twin-arginine translocons used by peroxisomes and plant thylakoid membranes^{96,97}. In addition, gp78, TEB4 and other ubiquitin ligases with multispinning membrane domains may be recruited into the dislocation complex. Furthermore, the translocon components Sec61 α and β have been suggested to be part of the “dislocon”^{1,85,127-130}. The advantage of forming a dislocon after the substrate has been defined is that it may be adapted to the nature of the substrate, e.g. the size of the substrate^{87,88}. Such an *ad hoc* arrangement would allow easy embrace of transmembrane regions of misfolded protein substrates CFTRdelta508^{98,99} and apolipoprotein B100^{100,101}. An additional advantage would be that the membrane integrity would stay intact since, before and after dislocation, there is no pore to keep closed in the absence of dislocation substrates¹⁰²⁻¹⁰⁵. Both the p97-Ufd1-Npl4 complex and the proteasome might be attracted by the dislocon, or even stabilize it⁶². Using either the ATPase activity of p97 or that of the proteasome, the dislocation substrate is extracted from the membrane and simultaneously unfolded and degraded by the proteasome. Just before proteasomal degradation, the N-glycanase may remove any N-linked glycans from the substrate^{106,107}. In the absence of proteasomal activity, the p97 complex extracts the substrate from the membrane⁶¹. In the absence of

ATPase activity in the p97 complex, the proteasome may facilitate both extraction and degradation ^{108,109}.

The future

Taken together, this thesis contributes to the partial characterization of an ER-route of degradation co-opted by HCMV to dispose of MHC class I molecules. For the future, it will be interesting to determine the exact definition of the dislocon and to ascertain whether there is only one type of dislocon in the ER or whether several different dislocon compositions for different groups of substrates exist. As to the value of the research described in this thesis in the quest for treatment of HCMV-related problems, it could be interesting to develop inhibitors of US2- and US11-class I interactions ¹¹⁰. This may contribute to the eradication of HCMV in HIV patients and patients receiving immunosuppressive drugs.

Besides CMV immune escape, this thesis deals with the role of ubiquitin in ER-associated degradation. After the discovery, in 1980, that ubiquitin was involved in protein turnover ^{111,112}, research on ubiquitin has expanded significantly and ubiquitin-dependent degradation is now an important issue in contemporary science. This is emphasized by the fact that Aaron Ciechanover, Avram Hershko, and Irwin Rose were awarded the Nobel Prize for Chemistry in 2004 for their work on ubiquitin. Defective ubiquitination of ER proteins forms the basis of such diseases as Alzheimer's disease ¹¹³⁻¹¹⁶, autosomal-recessive juvenile parkinsonism ¹¹⁷⁻¹²⁰, type 2 diabetes mellitus ¹²¹, and rheumatoid arthritis ^{122,123}. In addition, there are indications that ER stress ¹²⁴⁻¹²⁶ could be involved in the development of type 1 diabetes mellitus. These examples clearly illustrate the crucial importance of gaining fundamental insight into such cell biological issues as the role of the ubiquitin system in relation to the degradation of ER proteins described in this thesis.

References

- 1 Wiertz, E., Tortorella, D., Bogyo, M., Yu, J., Mothes, W., Jones, T., Rapoport, T. and Ploegh, H. (1996) Sec61-mediated transfer of a membrane protein from the endoplasmic reticulum to the proteasome for destruction. *Nature* **384**, 432-438
- 2 Wiertz, E., Jones, T., Sun, L., Bogyo, M., Geuze, H. and Ploegh, H. (1996) The human cytomegalovirus US11 gene product dislocates MHC class I heavy chains from the endoplasmic reticulum to the cytosol. *Cell* **84**, 769-779
- 3 van der Wal, F., Kikkert, M. and Wiertz, E. (2002) The HCMV gene products US2 and US11 target MHC class I molecules for degradation in the cytosol. *Curr.Top.Microbiol.Immunol.* **269**, 37-55
- 4 Gruhler, A. and Fruh, K. (2000) Control of MHC class I traffic from the endoplasmic reticulum by cellular chaperones and viral anti-chaperones. *Traffic*. **1**, 306-311

- 5 de Virgilio, M., Weninger, H. and Ivessa, N. (1998) Ubiquitination is required for the retrotranslocation of a short-lived luminal endoplasmic reticulum glycoprotein to the cytosol for degradation by the proteasome. *J.Biol.Chem.* **273**, 9734-9743
- 6 Shamu, C., Story, C., Rapoport, T. and Ploegh, H. (1999) The pathway of US11-dependent degradation of MHC class I heavy chains involves a ubiquitin-conjugated intermediate. *J.Cell Biol.* **147**, 45-58
- 7 Kikkert, M., Hassink, G., Barel, M., Hirsch, C., van der Wal, F. and Wiertz, E. (2001) Ubiquitination is essential for human cytomegalovirus US11-mediated dislocation of MHC class I molecules from the endoplasmic reticulum to the cytosol. *Biochem.J.* **358**, 369-377
- 8 Shamu, C., Flierman, D., Ploegh, H., Rapoport, T. and Chau, V. (2001) Polyubiquitination is required for US11-dependent movement of MHC class I heavy chain from endoplasmic reticulum into cytosol. *Mol.Biol.Cell* **12**, 2546-2555
- 9 Furman, M., Loureiro, J., Ploegh, H. and Tortorella, D. (2003) Ubiquitylation of the cytosolic domain of a type I membrane protein is not required to initiate its dislocation from the endoplasmic reticulum. *J.Biol.Chem.* **278**, 34804-34811
- 10 Flierman, D., Ye, Y., Dai, M., Chau, V. and Rapoport, T. (2003) Polyubiquitin serves as a recognition signal, rather than a ratcheting molecule, during retrotranslocation of proteins across the endoplasmic reticulum membrane. *J.Biol.Chem.* **278**, 34774-34782
- 11 del Val, M., Hengel, H., Hacker, H., Hartlaub, U., Ruppert, T., Lucin, P. and Koszinowski, U. (1992) Cytomegalovirus prevents antigen presentation by blocking the transport of peptide-loaded major histocompatibility complex class I molecules into the medial-Golgi compartment. *J.Exp.Med.* **176**, 729-738
- 12 Beersma, M., Bijlmakers, M. and Ploegh, H. (1993) Human cytomegalovirus down-regulates HLA class I expression by reducing the stability of class I H chains. *J.Immunol.* **151**, 4455-4464
- 13 Hassink, G., Duijvestijn-van Dam, J., Koppers-Lalic, D., Gaans-van den Brink, J., van Leeuwen, D., Vink, C., Bruggeman, C. and Wiertz, E. (2005) Rat cytomegalovirus induces a temporal downregulation of major histocompatibility complex class I cell surface expression. *Viral Immunol.* **18**, 607-615
- 14 Ahn, K., Angulo, A., Ghazal, P., Peterson, P., Yang, Y. and Fruh, K. (1996) Human cytomegalovirus inhibits antigen presentation by a sequential multistep process. *Proc.Natl.Acad.Sci.U.S.A* **93**, 10990-10995
- 15 Park, B., Kim, Y., Shin, J., Lee, S., Cho, K., Fruh, K., Lee, S. and Ahn, K. (2004) Human cytomegalovirus inhibits tapasin-dependent peptide loading and optimization of the MHC class I peptide cargo for immune evasion. *Immunity.* **20**, 71-85
- 16 Jones, T., Wiertz, E., Sun, L., Fish, K., Nelson, J. and Ploegh, H. (1996) Human cytomegalovirus US3 impairs transport and maturation of major histocompatibility complex class I heavy chains. *Proc.Natl.Acad.Sci.U.S.A* **93**, 11327-11333
- 17 Lee, S., Yoon, J., Park, B., Jun, Y., Jin, M., Sung, H., Kim, I., Kang, S., Choi, E., Ahn, B. and Ahn, K. (2000) Structural and functional dissection of human cytomegalovirus US3 in binding major histocompatibility complex class I molecules. *J.Virol.* **74**, 11262-11269
- 18 Jones, T., Hanson, L., Sun, L., Slater, J., Stenberg, R. and Campbell, A. (1995) Multiple independent loci within the human cytomegalovirus unique short region down-regulate expression of major histocompatibility complex class I heavy chains. *J.Virol.* **69**, 4830-4841
- 19 Jones, T. and Sun, L. (1997) Human cytomegalovirus US2 destabilizes major histocompatibility complex class I heavy chains. *J.Virol.* **71**, 2970-2979

- 20 Ahn, K., Gruhler, A., Galocha, B., Jones, T., Wiertz, E., Ploegh, H., Peterson, P., Yang, Y. and Fruh, K. (1997) The ER-luminal domain of the HCMV glycoprotein US6 inhibits peptide translocation by TAP. *Immunity*. **6**, 613-621
- 21 Hengel, H., Koopmann, J., Flohr, T., Muranyi, W., Goulmy, E., Hammerling, G., Koszinowski, U. and Momburg, F. (1997) A viral ER-resident glycoprotein inactivates the MHC-encoded peptide transporter. *Immunity*. **6**, 623-632
- 22 Hewitt, E., Gupta, S. and Lehner, P. (2001) The human cytomegalovirus gene product US6 inhibits ATP binding by TAP. *EMBO J.* **20**, 387-396
- 23 Kyritsis, C., Gorbulev, S., Hutschenreiter, S., Pawlitschko, K., Abele, R. and Tampe, R. (2001) Molecular mechanism and structural aspects of transporter associated with antigen processing inhibition by the cytomegalovirus protein US6. *J.Biol.Chem.* **276**, 48031-48039
- 24 Ziegler, H., Muranyi, W., Burgert, H., Kremmer, E. and Koszinowski, U. (2000) The luminal part of the murine cytomegalovirus glycoprotein gp40 catalyzes the retention of MHC class I molecules. *EMBO J.* **19**, 870-881
- 25 Ziegler, H., Thale, R., Lucin, P., Muranyi, W., Flohr, T., Hengel, H., Farrell, H., Rawlinson, W. and Koszinowski, U. (1997) A mouse cytomegalovirus glycoprotein retains MHC class I complexes in the ERGIC/cis-Golgi compartments. *Immunity*. **6**, 57-66
- 26 Helenius, A. (2001) Quality control in the secretory assembly line. *Philos.Trans.R.Soc.Lond B Biol.Sci.* **356**, 147-150
- 27 Dubois, M., Demick, K. and Mansfield, J. (2005) Trypanosomes expressing a mosaic variant surface glycoprotein coat escape early detection by the immune system. *Infect.Immun.* **73**, 2690-2697
- 28 Altfeld, M., Rosenberg, E., Shankarappa, R., Mukherjee, J., Hecht, F., Eldridge, R., Addo, M., Poon, S., Phillips, M., Robbins, G., Sax, P., Boswell, S., Kahn, J., Brander, C., Goulder, P., Levy, J., Mullins, J. and Walker, B. (2001) Cellular immune responses and viral diversity in individuals treated during acute and early HIV-1 infection. *J.Exp.Med.* **193**, 169-180
- 29 Albright, J., Jiang, D. and Albright, J. (1997) Innate control of the early course of infection in mice inoculated with *Trypanosoma muscliculi*. *Cell Immunol.* **176**, 146-152
- 30 Greijer, A., Adriaanse, H., Kahl, M., Tacken, N., Oldenburg, N., Sijlmans, A., van de Crommert, J., Dekkers, C., Sillekens, P. and Middeldorp, J. (2001) Quantitative competitive NASBA for measuring mRNA expression levels of the immediate early 1, late pp67, and immune evasion genes US3, US6 and US11 in cells infected with human cytomegalovirus. *J.Virol.Methods* **96**, 133-147
- 31 Park, B., Oh, H., Lee, S., Song, Y., Shin, J., Sung, Y., Hwang, S. and Ahn, K. (2002) The MHC class I homolog of human cytomegalovirus is resistant to down-regulation mediated by the unique short region protein (US)2, US3, US6, and US11 gene products. *J.Immunol.* **168**, 3464-3469
- 32 Hengel, H., Esslinger, C., Pool, J., Goulmy, E. and Koszinowski, U. (1995) Cytokines restore MHC class I complex formation and control antigen presentation in human cytomegalovirus-infected cells. *J.Gen.Virol.* **76 (Pt 12)**, 2987-2997
- 33 Koskinen, P., Kallio, E., Tikkanen, J., Sihvola, R., Hayry, P. and Lemstrom, K. (1999) Cytomegalovirus infection and cardiac allograft vasculopathy. *Transpl.Infect.Dis.* **1**, 115-126
- 34 Falk, C., Mach, M., Schendel, D., Weiss, E., Hilgert, I. and Hahn, G. (2002) NK cell activity during human cytomegalovirus infection is dominated by US2-11-mediated HLA class I down-regulation. *J.Immunol.* **169**, 3257-3266
- 35 Braud, V., Tomasec, P. and Wilkinson, G. (2002) Viral evasion of natural killer cells during human cytomegalovirus infection. *Curr.Top.Microbiol.Immunol.* **269**, 117-129

- 36 Fortis, C., Tasca, S., Capiluppi, B. and Tambussi, G. (2002) Natural killer cell function in HIV-1 infected patients. *J.Biol.Regul.Homeost.Agents* **16**, 30-32
- 37 Yu, H. and Kopito, R. (1999) The role of multiubiquitination in dislocation and degradation of the alpha subunit of the T cell antigen receptor. *J.Biol.Chem.* **274**, 36852-36858
- 38 Kikkert, M., Doolman, R., Dai, M., Avner, R., Hassink, G., Van Voorden, S., Thanedar, S., Roitelman, J., Chau, V. and Wiertz, E. (2003) Human Hrd1 is an E3 ubiquitin ligase involved in degradation of proteins from the endoplasmic reticulum. *J.Biol.Chem.* **279**, 3525-3534
- 39 Swanson, R., Locher, M. and Hochstrasser, M. (2001) A conserved ubiquitin ligase of the nuclear envelope/endoplasmic reticulum that functions in both ER-associated and Matalpha2 repressor degradation. *Genes Dev.* **15**, 2660-2674
- 40 Aasland, R., Gibson, T. and Stewart, A. (1995) The PHD finger: implications for chromatin-mediated transcriptional regulation. *Trends Biochem.Sci.* **20**, 56-59
- 41 Saha, V., Chaplin, T., Gregorini, A., Ayton, P. and Young, B. (1995) The leukemia-associated-protein (LAP) domain, a cysteine-rich motif, is present in a wide range of proteins, including MLL, AF10, and MLLT6 proteins. *Proc.Natl.Acad.Sci.U.S.A* **92**, 9737-9741
- 42 Lyngso, C., Bouteiller, G., Damgaard, C., Ryom, D., Sanchez-Munoz, S., Norby, P., Bonven, B. and Jorgensen, P. (2000) Interaction between the transcription factor SPBP and the positive cofactor RNF4. An interplay between protein binding zinc fingers. *J.Biol.Chem.* **275**, 26144-26149
- 43 Kosarev, P., Mayer, K. and Hardtke, C. (2002) Evaluation and classification of RING-finger domains encoded by the Arabidopsis genome. *Genome Biol.* **3**, research 0016-1-0016-2
- 44 Schindler, U., Beckmann, H. and Cashmore, A. (1993) HAT3.1, a novel Arabidopsis homeodomain protein containing a conserved cysteine-rich region. *Plant J.* **4**, 137-150
- 45 Aravind, L., Iyer, L. and Koonin, E. (2003) Scores of RINGS but No PHDs in Ubiquitin Signaling. *Cell Cycle* **2**, 123-126
- 46 Wang, Q. and Chang, A. (2003) Substrate recognition in ER-associated degradation mediated by Eps1, a member of the protein disulfide isomerase family. *EMBO J.* **22**, 3792-3802
- 47 Vashist, S. and Ng, D. (2004) Misfolded proteins are sorted by a sequential checkpoint mechanism of ER quality control. *J.Cell Biol.* **165**, 41-52
- 48 Patil, C. and Walter, P. (2001) Intracellular signaling from the endoplasmic reticulum to the nucleus: the unfolded protein response in yeast and mammals. *Curr.Opin.Cell Biol.* **13**, 349-355
- 49 Gnann, A., Riordan, J. and Wolf, D. (2004) CFTR Degradation Depends on the Lectins Htm1p/EDem and the Cdc48 Protein Complex in Yeast. *Mol.Biol.Cell* **15**, 4125-4135
- 50 Hitchcock, A., Auld, K., Gygi, S. and Silver, P. (2003) A subset of membrane-associated proteins is ubiquitinated in response to mutations in the endoplasmic reticulum degradation machinery. *Proc.Natl.Acad.Sci.U.S.A* **100**, 12735-12740
- 51 Hassink, G., Kikkert, M., Van Voorden, S., Lee, S., Spaapen, R., van Laar, T., Coleman, C., Bartee, E., Fruh, K., Chau, V. and Wiertz, E. (2005) TEB4 is a C4HC3 RING finger-containing ubiquitin ligase of the endoplasmic reticulum. *Biochem.J.* **388**, 647-655
- 52 Bartee, E., Mansouri, M., Hovey Nerenberg, B., Gouveia, K. and Fruh, K. (2004) Downregulation of major histocompatibility complex class I by human ubiquitin ligases related to viral immune evasion proteins. *J.Virol.* **78**, 1109-1120
- 53 Coscoy, L. and Ganem, D. (2000) Kaposi's sarcoma-associated herpesvirus encodes two proteins that block cell surface display of MHC class I chains by enhancing their endocytosis. *Proc.Natl.Acad.Sci.U.S.A* **97**, 8051-8056

- 54 Ishido, S., Choi, J., Lee, B., Wang, C., DeMaria, M., Johnson, R., Cohen, G. and Jung, J. (2000) Inhibition of natural killer cell-mediated cytotoxicity by Kaposi's sarcoma-associated herpesvirus K5 protein. *Immunity*. **13**, 365-374
- 55 Ishido, S., Wang, C., Lee, B., Cohen, G. and Jung, J. (2000) Downregulation of major histocompatibility complex class I molecules by Kaposi's sarcoma-associated herpesvirus K3 and K5 proteins. *J.Virol.* **74**, 5300-5309
- 56 Coscoy, L. and Ganem, D. (2001) A viral protein that selectively downregulates ICAM-1 and B7-2 and modulates T cell costimulation. *J.Clin.Invest* **107**, 1599-1606
- 57 Coscoy, L., Sanchez, D. and Ganem, D. (2001) A novel class of herpesvirus-encoded membrane-bound E3 ubiquitin ligases regulates endocytosis of proteins involved in immune recognition. *J.Cell Biol.* **155**, 1265-1273
- 58 Hewitt, E., Duncan, L., Mufti, D., Baker, J., Stevenson, P. and Lehner, P. (2002) Ubiquitylation of MHC class I by the K3 viral protein signals internalization and TSG101-dependent degradation. *EMBO J.* **21**, 2418-2429
- 59 Lorenzo, M., Jung, J. and Ploegh, H. (2002) Kaposi's sarcoma-associated herpesvirus K3 utilizes the ubiquitin-proteasome system in routing class major histocompatibility complexes to late endocytic compartments. *J.Virol.* **76**, 5522-5531
- 60 Biederer, T., Volkwein, C. and Sommer, T. (1997) Role of Cue1p in ubiquitination and degradation at the ER surface. *Science* **278**, 1806-1809
- 61 Elkabetz, Y., Shapira, I., Rabinovich, E. and Bar-Nun, S. (2004) Distinct steps in dislocation of luminal endoplasmic reticulum-associated degradation substrates: roles of endoplasmic reticulum-bound p97/Cdc48p and proteasome. *J.Biol.Chem.* **279**, 3980-3989
- 62 Ye, Y., Meyer, H. and Rapoport, T. (2001) The AAA ATPase Cdc48/p97 and its partners transport proteins from the ER into the cytosol. *Nature* **414**, 652-656
- 63 Yu, H., Kaung, G., Kobayashi, S. and Kopito, R. (1997) Cytosolic degradation of T-cell receptor alpha chains by the proteasome. *J.Biol.Chem.* **272**, 20800-20804
- 64 Dantuma, N., Lindsten, K., Glas, R., Jellne, M. and Masucci, M. (2000) Short-lived green fluorescent proteins for quantifying ubiquitin/proteasome-dependent proteolysis in living cells. *Nat.Biotechnol.* **18**, 538-543
- 65 Lindsten, K., de Vrij, F., Verhoef, L., Fischer, D., van Leeuwen, F., Hol, E., Masucci, M. and Dantuma, N. (2002) Mutant ubiquitin found in neurodegenerative disorders is a ubiquitin fusion degradation substrate that blocks proteasomal degradation. *J.Cell Biol.* **157**, 417-427
- 66 Schubert, U., Anton, L., Bacik, I., Cox, J., Bour, S., Bennink, J., Orłowski, M., Strelbel, K. and Yewdell, J. (1998) CD4 glycoprotein degradation induced by human immunodeficiency virus type 1 Vpu protein requires the function of proteasomes and the ubiquitin-conjugating pathway. *J.Virol.* **72**, 2280-2288
- 67 Tirosh, B., Iwakoshi, N., Lilley, B., Lee, A., Glimcher, L. and Ploegh, H. (2005) Human cytomegalovirus protein US11 provokes an unfolded protein response that may facilitate the degradation of class I major histocompatibility complex products. *J.Virol.* **79**, 2768-2779
- 68 Barel, M., Rensing, M., Pizzato, N., van Leeuwen, D., Le Bouteiller, P., Lenfant, F. and Wiertz, E. (2003) Human cytomegalovirus-encoded US2 differentially affects surface expression of MHC class I locus products and targets membrane-bound, but not soluble HLA-G1 for degradation. *J.Immunol.* **171**, 6757-6765
- 69 Ye, Y., Shibata, Y., Yun, C., Ron, D. and Rapoport, T. (2004) A membrane protein complex mediates retro-translocation from the ER lumen into the cytosol. *Nature* **429**, 841-847

- 70 Lilley, B. and Ploegh, H. (2004) A membrane protein required for dislocation of misfolded proteins from the ER. *Nature* **429**, 834-840
- 71 Hegde, N. and Johnson, D. (2003) Human cytomegalovirus US2 causes similar effects on both major histocompatibility complex class I and II proteins in epithelial and glial cells. *J.Virol.* **77**, 9287-9294
- 72 Chevalier, M., Daniels, G. and Johnson, D. (2002) Binding of human cytomegalovirus US2 to major histocompatibility complex class I and II proteins is not sufficient for their degradation. *J.Virol.* **76**, 8265-8275
- 73 Chevalier, M. and Johnson, D. (2003) Human cytomegalovirus US3 chimeras containing US2 cytosolic residues acquire major histocompatibility class I and II protein degradation properties. *J.Virol.* **77**, 4731-4738
- 74 Tomazin, R., Boname, J., Hegde, N., Lewinsohn, D., Altschuler, Y., Jones, T., Cresswell, P., Nelson, J., Riddell, S. and Johnson, D. (1999) Cytomegalovirus US2 destroys two components of the MHC class II pathway, preventing recognition by CD4+ T cells. *Nat.Med.* **5**, 1039-1043
- 75 Barel, M., Pizzato, N., van Leeuwen, D., Bouteiller, P., Wiertz, E. and Lenfant, F. (2003) Amino acid composition of alpha1/alpha2 domains and cytoplasmic tail of MHC class I molecules determine their susceptibility to human cytomegalovirus US11-mediated down-regulation. *Eur.J.Immunol.* **33**, 1707-1716
- 76 Story, C., Furman, M. and Ploegh, H. (1999) The cytosolic tail of class I MHC heavy chain is required for its dislocation by the human cytomegalovirus US2 and US11 gene products. *Proc.Nat.Acad.Sci.U.S.A* **96**, 8516-8521
- 77 Furman, M., Ploegh, H. and Tortorella, D. (2002) Membrane-specific, host-derived factors are required for US2- and US11-mediated degradation of major histocompatibility complex class I molecules. *J.Biol.Chem.* **277**, 3258-3267
- 78 Blom, D., Hirsch, C., Stern, P., Tortorella, D. and Ploegh, H. (2004) A glycosylated type I membrane protein becomes cytosolic when peptide: N-glycanase is compromised. *EMBO J.* **23**, 650-658
- 79 Whitman, M., Strohmaier, J., O'Boyle, K., Tingem, J., Wilkinson, Y., Goldstein, J., Chen, T., Brorson, K., Brunswick, M. and Kozlowski, S. (2000) The isolated major histocompatibility complex class I alpha3 domain binds beta2m and CD8alphaalpha dimers. *Mol.Immunol.* **37**, 141-149
- 80 Luthra-Guptasarma, M. and Singh, B. (2004) HLA-B27 lacking associated beta2-microglobulin rearranges to auto-display or cross-display residues 169-181: a novel molecular mechanism for spondyloarthropathies. *FEBS Lett.* **575**, 1-8
- 81 Hill, D., Kasliwal, T., Schwarz, E., Hebert, A., Chen, T., Gubina, E., Zhang, L. and Kozlowski, S. (2003) A dominant negative mutant beta 2-microglobulin blocks the extracellular folding of a major histocompatibility complex class I heavy chain. *J.Biol.Chem.* **278**, 5630-5638
- 82 Barel, M., Hassink, G., Voorden, S. and Wiertz, E. (2006) Human cytomegalovirus-encoded US2 and US11 target unassembled MHC class I heavy chains for degradation. *Mol.Immunol.* **43**, 1258-1266
- 83 Bebok, Z., Mazzochi, C., King, S., Hong, J. and Sorscher, E. (1998) The mechanism underlying cystic fibrosis transmembrane conductance regulator transport from the endoplasmic reticulum to the proteasome includes Sec61beta and a cytosolic, deglycosylated intermediary. *J.Biol.Chem.* **273**, 29873-29878
- 84 Plemper, R., Bohmler, S., Bordallo, J., Sommer, T. and Wolf, D. (1997) Mutant analysis links the translocon and BiP to retrograde protein transport for ER degradation. *Nature* **388**, 891-895

- 85 Plempner, R., Egner, R., Kuchler, K. and Wolf, D. (1998) Endoplasmic reticulum degradation of a mutated ATP-binding cassette transporter Pdr5 proceeds in a concerted action of Sec61 and the proteasome. *J.Biol.Chem.* **273**, 32848-32856
- 86 Hamman, B., Chen, J., Johnson, E. and Johnson, A. (1997) The aqueous pore through the translocon has a diameter of 40-60 Å during cotranslational protein translocation at the ER membrane. *Cell* **89**, 535-544
- 87 Fiebigler, E., Story, C., Ploegh, H. and Tortorella, D. (2002) Visualization of the ER-to-cytosol dislocation reaction of a type I membrane protein. *EMBO J.* **21**, 1041-1053
- 88 Tirosh, B., Furman, M., Tortorella, D. and Ploegh, H. (2003) Protein unfolding is not a prerequisite for endoplasmic reticulum-to-cytosol dislocation. *J.Biol.Chem.* **278**, 6664-6672
- 89 Johnson, A. and van Waes, M. (1999) The translocon: a dynamic gateway at the ER membrane. *Annu.Rev.Cell Dev.Biol.* **15**, 799-842
- 90 Johnson, A. and Haigh, N. (2000) The ER translocon and retrotranslocation: is the shift into reverse manual or automatic? *Cell* **102**, 709-712
- 91 Tsai, B. and Rapoport, T. (2002) Unfolded cholera toxin is transferred to the ER membrane and released from protein disulfide isomerase upon oxidation by Ero1. *J.Cell Biol.* **159**, 207-216
- 92 Perozo, E., Cortes, D., Sompornpisut, P., Kloda, A. and Martinac, B. (2002) Open channel structure of MscL and the gating mechanism of mechanosensitive channels. *Nature* **418**, 942-948
- 93 Ye, Y., Shibata, Y., Kikkert, M., Van Voorden, S., Wiertz, E. and Rapoport, T. (2005) Inaugural Article: Recruitment of the p97 ATPase and ubiquitin ligases to the site of retrotranslocation at the endoplasmic reticulum membrane. *Proc.Natl.Acad.Sci.U.S.A* **102**, 14132-14138
- 94 Lilley, B. and Ploegh, H. (2005) Multiprotein complexes that link dislocation, ubiquitination, and extraction of misfolded proteins from the endoplasmic reticulum membrane. *Proc.Natl.Acad.Sci.U.S.A* **102**, 14296-14301
- 95 Schulze, A., Standera, S., Buerger, E., Kikkert, M., Van Voorden, S., Wiertz, E., Koning, F., Kloetzel, P. and Seeger, M. (2005) The Ubiquitin-domain Protein HERP forms a Complex with Components of the Endoplasmic Reticulum Associated Degradation Pathway. *J.Mol.Biol.* **354**, 1021-1027
- 96 Schnell, D. and Hebert, D. (2003) Protein translocons: multifunctional mediators of protein translocation across membranes. *Cell* **112**, 491-505
- 97 Mori, H. and Cline, K. (2002) A twin arginine signal peptide and the pH gradient trigger reversible assembly of the thylakoid Δ pH/Tat translocase. *J.Cell Biol.* **157**, 205-210
- 98 Ward, C., Omura, S. and Kopito, R. (1995) Degradation of CFTR by the ubiquitin-proteasome pathway. *Cell* **83**, 121-127
- 99 Xiong, X., Chong, E. and Skach, W. (1999) Evidence that endoplasmic reticulum (ER)-associated degradation of cystic fibrosis transmembrane conductance regulator is linked to retrograde translocation from the ER membrane. *J.Biol.Chem.* **274**, 2616-2624
- 100 Zhou, M., Fisher, E. and Ginsberg, H. (1998) Regulated Co-translational ubiquitination of apolipoprotein B100. A new paradigm for proteasomal degradation of a secretory protein. *J.Biol.Chem.* **273**, 24649-24653
- 101 Liang, J., Kim, T., Fang, S., Yamaguchi, J., Weissman, A., Fisher, E. and Ginsberg, H. (2003) Overexpression of the tumor autocrine motility factor receptor Gp78, a ubiquitin protein ligase, results in increased ubiquitinylation and decreased secretion of apolipoprotein B100 in HepG2 cells. *J.Biol.Chem.* **278**, 23984-23988

- 102 Teter, S. and Klionsky, D. (1999) How to get a folded protein across a membrane. *Trends Cell Biol.* **9**, 428-431
- 103 Van den Berg, Clemons, W., Jr., Collinson, I., Modis, Y., Hartmann, E., Harrison, S. and Rapoport, T. (2004) X-ray structure of a protein-conducting channel. *Nature* **427**, 36-44
- 104 Alder, N., Shen, Y., Brodsky, J., Hendershot, L. and Johnson, A. (2005) The molecular mechanisms underlying BiP-mediated gating of the Sec61 translocon of the endoplasmic reticulum. *J.Cell Biol.* **168**, 389-399
- 105 Hamman, B., Hendershot, L. and Johnson, A. (1998) BiP maintains the permeability barrier of the ER membrane by sealing the luminal end of the translocon pore before and early in translocation. *Cell* **92**, 747-758
- 106 Suzuki, T., Park, H., Till, E. and Lennarz, W. (2001) The PUB domain: a putative protein-protein interaction domain implicated in the ubiquitin-proteasome pathway. *Biochem.Biophys.Res.Commun.* **287**, 1083-1087
- 107 Schaubert, C., Chen, L., Tongaonkar, P., Vega, I., Lambertson, D., Potts, W. and Madura, K. (1998) Rad23 links DNA repair to the ubiquitin/proteasome pathway. *Nature* **391**, 715-718
- 108 Baumeister, W., Walz, J., Zuhl, F. and Seemuller, E. (1998) The proteasome: paradigm of a self-compartmentalizing protease. *Cell* **92**, 367-380
- 109 Ye, Y., Meyer, H. and Rapoport, T. (2003) Function of the p97-Ufd1-Npl4 complex in retrotranslocation from the ER to the cytosol: dual recognition of nonubiquitinated polypeptide segments and polyubiquitin chains. *J.Cell Biol.* **162**, 71-84
- 110 Fiebigler, E., Hirsch, C., Vyas, J., Gordon, E., Ploegh, H. and Tortorella, D. (2004) Dissection of the dislocation pathway for type I membrane proteins with a new small molecule inhibitor, eeyarestatin. *Mol.Biol.Cell* **15**, 1635-1646
- 111 Ciechanover, A., Elias, S., Heller, H., Ferber, S. and Hershko, A. (1980) Characterization of the heat-stable polypeptide of the ATP-dependent proteolytic system from reticulocytes. *J.Biol.Chem.* **255**, 7525-7528
- 112 Hershko, A., Ciechanover, A., Heller, H., Haas, A. and Rose, I. (1980) Proposed role of ATP in protein breakdown: conjugation of protein with multiple chains of the polypeptide of ATP-dependent proteolysis. *Proc.Natl.Acad.Sci.U.S.A* **77**, 1783-1786
- 113 Perry, G., Friedman, R., Shaw, G. and Chau, V. (1987) Ubiquitin is detected in neurofibrillary tangles and senile plaque neurites of Alzheimer disease brains. *Proc.Natl.Acad.Sci.U.S.A* **84**, 3033-3036
- 114 van Leeuwen, F., de Kleijn, D., van den Hurk, H., Neubauer, A., Sonnemans, M., Sluijs, J., Koycu, S., Ramdjelal, R., Salehi, A., Martens, G., Grosveld, F., Peter, J., Burbach, H. and Hol, E. (1998) Frameshift mutants of beta amyloid precursor protein and ubiquitin-B in Alzheimer's and Down patients. *Science* **279**, 242-247
- 115 van Laar, T., van der Eb, A. and Terleth, C. (2001) Mif1: a missing link between the unfolded protein response pathway and ER-associated protein degradation? *Curr.Protein Pept.Sci.* **2**, 169-190
- 116 Hatakeyama, S., Matsumoto, M., Kamura, T., Murayama, M., Chui, D., Planel, E., Takahashi, R., Nakayama, K. and Takashima, A. (2004) U-box protein carboxyl terminus of Hsc70-interacting protein (CHIP) mediates poly-ubiquitylation preferentially on four-repeat Tau and is involved in neurodegeneration of tauopathy. *J.Neurochem.* **91**, 299-307
- 117 Manetto, V., Perry, G., Tabaton, M., Mulvihill, P., Fried, V., Smith, H., Gambetti, P. and Autilio-Gambetti, L. (1988) Ubiquitin is associated with abnormal cytoplasmic filaments characteristic of neurodegenerative diseases. *Proc.Natl.Acad.Sci.U.S.A* **85**, 4501-4505

- 118 Shimura, H., Hattori, N., Kubo, S., Mizuno, Y., Asakawa, S., Minoshima, S., Shimizu, N., Iwai, K., Chiba, T., Tanaka, K. and Suzuki, T. (2000) Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase. *Nat.Genet.* **25**, 302-305
- 119 Takahashi, R. and Imai, Y. (2003) Pael receptor, endoplasmic reticulum stress, and Parkinson's disease. *J.Neurol.* **250 Suppl 3**, III25-III29
- 120 Takahashi, R., Imai, Y., Hattori, N. and Mizuno, Y. (2003) Parkin and endoplasmic reticulum stress. *Ann.N.Y.Acad.Sci.* **991**, 101-106
- 121 Allen, J., Nguyen, L., Sargent, K., Lipson, K., Hackett, A. and Urano, F. (2004) High ER stress in beta-cells stimulates intracellular degradation of misfolded insulin. *Biochem.Biophys.Res.Commun.* **324**, 166-170
- 122 Muller, S., Briand, J. and Van Regenmortel, M. (1988) Presence of antibodies to ubiquitin during the autoimmune response associated with systemic lupus erythematosus. *Proc.Natl.Acad.Sci.U.S.A* **85**, 8176-8180
- 123 Amano, T., Yamasaki, S., Yagishita, N., Tsuchimochi, K., Shin, H., Kawahara, K., Aratani, S., Fujita, H., Zhang, L., Ikeda, R., Fujii, R., Miura, N., Komiyama, S., Nishioka, K., Maruyama, I., Fukamizu, A. and Nakajima, T. (2003) Synoviolin/Hrd1, an E3 ubiquitin ligase, as a novel pathogenic factor for arthropathy. *Genes Dev.* **17**, 2436-2449
- 124 Harding, H. and Ron, D. (2002) Endoplasmic reticulum stress and the development of diabetes: a review. *Diabetes* **51 Suppl 3**, S455-S461
- 125 Araki, E., Oyadomari, S. and Mori, M. (2003) Endoplasmic reticulum stress and diabetes mellitus. *Intern.Med.* **42**, 7-14
- 126 Julier, C. (2001) Lost in translation. *Nat.Genet.* **29**, 358-359
- 127 Bordallo, J., Plemper, R., Finger, A. and Wolf, D. (1998) Der3p/Hrd1p is required for endoplasmic reticulum-associated degradation of misfolded luminal and integral membrane proteins. *Mol.Biol.Cell* **9**, 209-222
- 128 Pilon, M., Romisch, K., Quach, D. and Schekman, R. (1998) Sec61p serves multiple roles in secretory precursor binding and translocation into the endoplasmic reticulum membrane. *Mol.Biol.Cell* **9**, 3455-3473
- 129 Sommer, T. and Jentsch, S. (1993) A protein translocation defect linked to ubiquitin conjugation at the endoplasmic reticulum. *Nature* **365**, 176-179
- 130 Gillece, P., Pilon, M. and Romisch, K. (2000) The protein translocation channel mediates glycopeptide export across the endoplasmic reticulum membrane. *Proc.Natl.Acad.Sci.U.S.A* **97**, 4609-4614
- 131 Rabinovich E, Kerem A, Frohlich KU, Diamant N, Bar-Nun S (2002) AAA-ATPase p97/Cdc48p, a cytosolic chaperone required for endoplasmic reticulum-associated protein degradation. *Mol Cell Biol* **22**, 626-34